Novartis Institute for Tropical Diseases

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Novartis Institute for Tropical Diseases, Research, Acute myeloid leukemia, Food, Disclosure, HIV disease progression rates, Syndrome, SITC, Annual general meeting, HCT, RIC, Society for Immunotherapy of Cancer, MDS, Neoplasm, KOL, Amgen, Cancer, Therapy, Patient, Food and Drug Administration, MAGE-C2, Acute leukemia, ASH, Heme, City, Immunotherapy, Clinical trial, Biomedical Research, PRAME, TCR, Society, HLA, Investigational New Drug, ALL, Haematopoietic system, FDA, Antigen, Trial of the century, IND, C2, Poster, Collection, Associate, AML, Vaccine, Security (finance), Pharmaceutical industry, Medical imaging, Hematology, Melanoma

WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results and provided a corporate update for the third quarter ended September 30, 2023.

Key Points: 
  • As of September 30, 2023, TScan Therapeutics had cash, cash equivalents, and marketable securities of $215.4 million, excluding $5.0 million of restricted cash.
  • Revenue for the third quarter ended September 30, 2023, was $3.9 million, compared to $3.4 million for the third quarter ended September 30, 2022 (2022 Quarter).
  • Research and development expenses for the third quarter ended September 30, 2023, were $22.7 million, compared to $15.0 million for the 2022 Quarter.
  • For the third quarter ended September 30, 2023, TScan Therapeutics reported a net loss of $23.0 million, compared to a net loss of $16.2 million for the 2022 Quarter.

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Novartis Institute for Tropical Diseases, Trial of the century, AACR, ESMO, Progression-free survival, Biomedical Research, Congress, European Society for Medical Oncology, PFS, Conference, GAAP, Research, R, Ribociclib, ESR1, Novartis, Clinical trial, Silicon Valley Bank, Cancer, Oncology, CBR, Table, Patient, Breast, SAN, Pharmaceutical industry, Cryptocurrency, Medical imaging, G&A

Presented palazestrant Phase 2 monotherapy clinical study results as an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

Key Points: 
  • Presented palazestrant Phase 2 monotherapy clinical study results as an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.
  • Non-GAAP R&D expenses were $16.7 million for the quarter ended September 30, 2023, excluding $2.8 million non-cash stock-based compensation expense.
  • Non-GAAP G&A expenses were $2.6 million for the quarter ended September 30, 2023, excluding $1.3 million non-cash stock-based compensation expense.
  • Non-GAAP G&A expenses were $4.1 million for the quarter ended September 30, 2022, excluding $1.5 million non-cash stock-based compensation expense.

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Novartis Institute for Tropical Diseases, Research, NSCLC, Acute myeloid leukemia, IMGN, Food, PIN, Biomedical Research, ImmunoGen, European Medicines Agency, Doctor of Philosophy, Medicine, Capital expenditure, New Drug Application, Takeda Pharmaceutical Company, Marketing, BPDCN, ESGO, US Foods, Azacitidine, European Society of Gynaecological Oncology, EMA, ORR, NDA, Safety, Cancer, György Enyedi (geographer), Patient, National Medical Products Administration, Eli Lilly and Company, MAA, Congress, Mirvetuximab soravtansine, Blastic plasmacytoid dendritic cell neoplasm, ASH, Growth, ADC, Spacecraft, FDA, NMPA, PROC, University Clinical Centre in Gdańsk, Society, Senior, Inc., Huadong Medicine, AML, PARP, Vaccine, Pharmaceutical industry, Dietary supplement, Takeda

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
  • We also continued to monitor the NSCLC cohort with IMGC936 and advanced dose escalation with IMGN151, our second-generation ADC targeting FRα.
  • Selling, general and administrative expenses were $37.7 million for the quarter ended September 30, 2023 compared to $33.6 million for the quarter ended September 30, 2022.
  • Capital expenditures were $1.6 million and $1.1 million for the first nine months of 2023 and 2022, respectively.

Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

Retrieved on: 
Tuesday, October 10, 2023
Biomedical Research, SAN, Safety, Novartis Institute for Tropical Diseases, Novartis, Patient, Trial of the century, Ribociclib, Pharmaceutical industry

SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced an amendment to our existing clinical collaboration and supply agreement with Novartis Institutes for BioMedical Research, Inc. (“Novartis”) to increase the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib to approximately 60 patients.

Key Points: 
  • SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced an amendment to our existing clinical collaboration and supply agreement with Novartis Institutes for BioMedical Research, Inc. (“Novartis”) to increase the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib to approximately 60 patients.
  • “The amendment announced today significantly increases the size of our ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib, in collaboration with Novartis,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.
  • “With the Phase 1b dose escalation portion now successfully completed, we are currently in Phase 2 dose expansion at the 120 mg dose of palazestrant in combination with 600 mg of ribociclib.
  • The amendment adds approximately 30 patients to be enrolled in the cohort expansion phase of the palazestrant clinical study in combination with ribociclib.

ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer

Retrieved on: 
Monday, September 18, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Boston Consulting Group, BS, Novartis Institute for Tropical Diseases, Biomedical Research, General Electric, Senior, NIBR, Carroll School of Management, Cancer, MBA, Finance, ImmunoGen, IMGN, Accounting, Novartis, Patient, Analysis, Executive Committee, Harvard Business School, Growth, Boston College, Spacecraft, Executive Committee of the Space Research Council, Therapy, Management, Malaria

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Lauren White has been appointed Senior Vice President and Chief Financial Officer.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Lauren White has been appointed Senior Vice President and Chief Financial Officer.
  • "We are excited to have Lauren join our team and believe that her expertise in financial planning and strategy, operations, and investor relations will be invaluable as we evolve as a fully-integrated oncology company," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer.
  • She joins ImmunoGen from C4 Therapeutics, where she served as Chief Financial Officer, Treasurer, and Principal Accounting Officer, developing and leading the Company's financial strategy and operations.
  • Prior to this role, she launched the global health business unit as Chief Financial Officer in Basel, Switzerland, and was responsible for several franchises globally.

Ajax Therapeutics Appoints Dr. David Steensma as Chief Medical Officer

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Ruxolitinib, Novartis Institute for Tropical Diseases, Mayo Clinic, University, Oncology Drug Advisory Committee, Journal of Clinical Oncology, JAK, Type 2, Bone marrow, FACP, ODAC, Multimedia, Biomedical Research, Computational chemistry, Dana–Farber Cancer Institute, MDS, Harvard Medical School, Pancreatic serous cystadenoma, Bone marrow failure, Journal, Ajax, MD, Translational research, American Society of Hematology, Patient, Division, Edward, Memorial Sloan Kettering Cancer Center, Clinical professor, Research, FDA, Therapy, Malignancy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Myelodysplastic syndrome, Disease, Pharmaceutical industry, Nursing, Hematology, Leukemia

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the appointment of David P. Steensma, MD, FACP, as Chief Medical Officer.

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the appointment of David P. Steensma, MD, FACP, as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230823046723/en/
    Ajax Therapeutics CMO David Steensma, MD, FACP (Photo: Business Wire)
    “We are very fortunate to have such a veteran hematology drug developer as David join the Ajax team as we near the clinic with our next generation Type II JAK2 inhibitor program for MPNs,” said Martin Vogelbaum, CEO of Ajax Therapeutics.
  • Dr. Steensma has published over 200 original research papers as well as numerous reviews, editorials and book chapters.
  • He received his medical degree from the University of Chicago’s Pritzker School of Medicine.

Ray Therapeutics Announces Promotion of Jenny Holt to Chief Development Officer

Retrieved on: 
Monday, August 21, 2023
Health, Genetics, Research, Science, Pharmaceutical, Optical, Biotechnology, Immunotherapy, Novartis Institute for Tropical Diseases, Multimedia, Retina, Biomedical Research, Onyx Pharmaceuticals, AAV, UC, Patient, UCSF, Ophthalmology, Growth, Therapy, Pfizer, University of California, Santa Barbara, Pharmaceutical industry

Ray Therapeutics , a leading optogenetics medicines company, today announced the promotion of Jenny Holt to Chief Development Officer.

Key Points: 
  • Ray Therapeutics , a leading optogenetics medicines company, today announced the promotion of Jenny Holt to Chief Development Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230821437345/en/
    “Since joining the Company in 2022 as Senior Vice President, Program Portfolio Management, Jenny has demonstrated exceptional leadership and has played a critical role in the growth and accomplishments of Ray Therapeutics,” said Paul Bresge, Chief Executive Officer.
  • “She has played an integral part in advancing our programs and I am pleased to announce her well-deserved promotion to Chief Development Officer.
  • Prior to joining Ray Therapeutics, Jenny was previously at 4D Molecular Therapeutics, a leading AAV-based gene therapy company, where she managed five gene therapy products from discovery to early-stage clinical development.

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Novartis Institute for Tropical Diseases, Gene, HLA, ALL, MAGE-A1, Papillomaviridae, Clinical trial, HPV16, Cancer, Biomedical Research, PRAME, TCR, MDS, E7, ASCO, Acute myeloid leukemia, Trial of the century, AML, American Society of Clinical Oncology, Patient, Syndrome, Annual general meeting, Cell, Acute leukemia, IND Culver Line, Toxic shock syndrome toxin-1, Poster, Research, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Safety, Society, Food, Pharmaceutical industry, Life insurance, Video game, Amgen

WALTHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor-engineered T cell therapies (TCR-Ts) for the treatment of patients with cancer, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023.

Key Points: 
  • Revenue for the second quarter ended June 30, 2023, was $3.1 million, compared to $4.1 million for the second quarter ended June 30, 2022 (2022 Quarter).
  • Research and development expenses for the second quarter ended June 30, 2023, were $21.2 million, compared to $14.5 million for the 2022 Quarter.
  • General and administrative expenses for the second quarter ended June 30, 2023, were $6.5 million, compared to $4.8 million for the 2022 Quarter.
  • For the second quarter ended June 30, 2023, TScan Therapeutics reported a net loss of $24.0 million, compared to a net loss of $15.1 million for the 2022 Quarter.

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

Retrieved on: 
Monday, August 7, 2023
Takeda Pharmaceutical Company, Business development, Partnership, Novartis Institute for Tropical Diseases, University, Gastroenterology, Doctor of Philosophy, Takeda, Head, Physician, Roche, University of California, Research, Biomedical Research, Strategic planning, Rutgers University, Gastrointestinal tract, Novartis, Patient, Columbia University Vagelos College of Physicians and Surgeons, CBO, M.A, Therapy, Neurology, Pharmaceutical industry, Neuroscience, Voyager, Ophthalmology, Surgeon

CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO).

Key Points: 
  • CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO).
  • Shafer is a seasoned healthcare executive with more than 15 years of experience in corporate and business development at prominent biopharmaceutical companies, as well as deep knowledge in neurology.
  • She previously held multiple corporate and business development roles of increasing responsibility during her tenures at Takeda, Novartis and Roche.
  • “I look forward to helping the team leverage business development and strategy to achieve its mission of advancing life-changing genetic medicines for neurological diseases.”

Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors

Retrieved on: 
Monday, July 24, 2023
Linda, Business development, Novartis Institute for Tropical Diseases, Drug development, Duchenne muscular dystrophy, Therapy, NIBR, University, Biogen, Exosome, Program management, Research, Biomedical Research, CAR, Philip, Vaccine, Patient, SAN, MUSCULAR, Berkeley, Harvard Business School, Drug discovery, Amherst College, Growth, Neurology, Autoimmunity, Massachusetts Institute of Technology, Pharmaceutical industry, Management, Genetics, Novartis, Biology

"It is a pleasure to welcome Philip to our Board of Directors," said Linda Marbán, Ph.D., Capricor’s chief executive officer.

Key Points: 
  • "It is a pleasure to welcome Philip to our Board of Directors," said Linda Marbán, Ph.D., Capricor’s chief executive officer.
  • "Philip has a strong track record for leading research and development programs, from drug discovery through commercialization.
  • His scientific acumen and ability to strategically drive forward business development for research will be invaluable as we continue efforts to advance our cell and exosome technologies.
  • Philip is a tremendous addition to our board, and we look forward to working with him.”
    Dr. Gotwals added, "I am delighted to join Capricor as a member of the board of directors.